MacroGenics enters the back half of May with fresh earnings momentum — Q1 results just crossed the wire, and shorts who built positions over the past month are now sitting on a 19% one-day jump.
The earnings print delivered two surprises. Revenue of $20.8 million beat estimates of $15.1 million by nearly 38%. EPS of -$0.58 beat the -$0.65 consensus. Alongside the results, the company announced that Bora has signed a $122.5 million takeover of its manufacturing facility — a meaningful asset sale for a company whose enterprise value clocks in around $49 million. The facility deal reshapes the balance sheet narrative entirely. For a stock that spent most of April trading near $3, suddenly the math looks very different.
The short positioning story is mild but worth tracking. Short interest is running at roughly 4.8% of free float — not extreme, but up about 2.5% over the past week as some traders added exposure ahead of the print. That position just got squeezed. Borrow costs had spiked to over 4.5% in early May but have since eased back to 0.73%, well below recent highs. Availability in the lending pool remains very loose — the borrow market is not stressed. Combined with a short score of 38.8, this does not look like a heavily contested name heading into any structural squeeze; the move is more about trapped weekly shorts than a crowded structural position.
Options positioning shifted ahead of the number. The put/call ratio reached 0.26, nearly 1.8 standard deviations above its 20-day average of 0.15 — the highest defensive reading in several weeks. That hedging demand proved unnecessary for put holders. With the 52-week PCR high sitting at 1.08, the ratio is still far from extreme bearishness, but the directional reset from this week's call-light positioning is notable.
The analyst picture has been quietly turning. Barclays maintained its Overweight on April 20 and raised its target from $4 to $6 — a 50% increase — just weeks before a print that validated the thesis. B. Riley upgraded to Buy in April with a $9 target, up from $3, making it the most aggressive bull on the desk. The consensus remains a Hold with four analysts sitting neutral, but the direction of travel in April was constructive. The $6 Barclays target and $9 B. Riley target both sit well above the current $3.52 close — though note these targets were set before the earnings beat and facility sale were fully digested. The EPS surprise factor score ranks in the 98th percentile of its universe, consistent with a company that has a habit of clearing the bar.
Earnings history reinforces why the stock is volatile around events. The March 2026 print produced a 54% one-day gain. The prior November 2025 event moved the stock 10% in a day. Even a miss in November 2025 only caused an 11% decline. The pattern is consistent: this is a name that moves hard on numbers, and the moves tend to extend over five days. The five-day aftermath of the March beat ran to +39%. Whether this week's print follows a similar trajectory depends on how the market digests the Bora facility deal and what management says about the pipeline in the earnings call.
The next session is therefore less about whether the beat sustains and more about whether the $122.5 million facility transaction — and what it implies for the company's future capital needs — changes the picture for the remaining holders, who are now looking at a stock double its February lows.
See the live data behind this article on ORTEX.
Open MGNX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
